ArticleScientific reports2025
Interleukin-6 accelerates the progression of warm autoimmune hemolytic anemia by affecting the DNA methylation status of peripheral blood B lymphocytes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interleukin-6 in hemolytic anemias: from inflammatory pathways to therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
DNA methylation of peripheral blood (PB) B cells of warm autoimmune hemolytic anemia (wAIHA) patient was investigated. B cell DNA methylation level and the methylation-regulatory genes mRNA from 34 wAIHA patients and 16 healthy controls (HCs) were detected. The correlation between B cell DNA methylation and clinical indicators was analyzed. The effects of IL-6 on the B cell DNA methylation were examined. B cell DNA methylation level and DNMT1 mRNA expression of hemolytic episode patients were lower than that in remission patients and HCs. B cell DNA methylation in glucocorticoid-resistant patients was low. The hemolytic degree, response and relapse rate were correlated with B cell DNA methylation. Serum IL-6 concentration in hemolytic episode patients was higher than that in HCs and IL-6 inhibited DNMT1 expression in B cell of patients. IL-6 may inhibit the B cell DNA methylation levels and methylation regulatory genes of wAIHA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.